The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The study’s authors, led by Lihua E Budde, MD, PhD, of City of Hope in Duarte, California, published the findings in the Journal of Hematology & Oncology.
Clinical investigators are actively evaluating these novel agents across several strategic combinations and settings, Prof. Weisel explained.
“We have very interesting maintenance trials,” she noted, “where iberdomide is tested as a monotherapy or even in combination with monoclonal anti-CD38 antibodies.”
The approval is based on the Phase 2/3 ENERGY study, the full results of which were presented at the European Hematology Association 2026 meeting in June.
The China National Medical Products Administration (NMPA) has approved felzartamab (Jingfei), a human monoclonal antibody targeting CD38, in combination with lenalidomide and dexamethasone for adult
About half of patients (n=232; 51.5%) were treated with ATO/ATRA alone, while 86 (19.1%) underwent intensified therapy with chemotherapy in addition to ATO and/or ATRA.
He explains how this in vivo lentiviral vector infusion aims to eliminate traditional manufacturing barriers by shifting the cell engineering process directly into the patient’s body.
SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.
To access the SOHO Career Center click the following link.
